The global tuberculosis vaccine market is anticipated to grow at a CAGR of 8.4% during the forecast period. Tuberculosis vaccine such as BCG (stands for Bacille Calmette-Guérin) is the most widely used tuberculosis vaccine and are being commercialized for the prevention of tuberculosis. Various advancements in the areas of mycobacterial immunology and genomics have fueled the research on multiple new experimental vaccines that is the key factor driving the market growth. In addition to this, the relatively low cost of these vaccines, as well as the easy availability of the vaccine are the major drivers of the industry growth. With an increase in the number of tuberculosis cases globally, the demand for tuberculosis vaccines is projected to increase more, thereby driving the market growth. As per WHO, a total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). In the same year, 1.1 million children fell ill with TB globally. TB is the 13th leading cause of death and the second leading infectious killer after COVID-19. 

Moreover, the growth in the technological advancements for vaccine research, rising government initiatives, and emphasis on immunization programs all over the globe will also boost the market growth during the forecast period. However, the side effect such as high temperature, headache, swollen glands under the armpit, and soreness or discharge where the injection was given, associated with the vaccine may act as restrain the further growth of the market. 

Segmental Outlook  

The global tuberculosis vaccine market is segmented based on type and application. Based on type, the market is bifurcated into immunotherapeutic vaccines and booster vaccines. Among these, the immunotherapeutic vaccine segment is going to dominate by accounting highest share and is also expected to be the fastest-growing during the forecast period. Immunotherapeutic vaccine such as Bacille Calmette-Guérin (BCG) is prescribed for tuberculosis disease prevention. It provides consistent protection against the most severe forms of TB, such as TB meningitis in children. An increase in the number of newborn babies and the prevalence of pediatric tuberculosis is likely to drive segment expansion. As per CDC, in 2020, there were 317 cases of TB disease among children ages 14 years or younger in the US, accounting for 4% of all people reported with TB nationally. Based on application, the market is further sub-categorized into hospitals, clinics, and others. 

Regional Outlook 

Geographically, the global tuberculosis vaccine market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). The Europe region is likely to hold considerable market share during the forecast period owing to the rapid increase in the number of tuberculosis cases that are generating product demand. As per the European Centre for Disease Prevention and Control, in  2019, 49 752 cases of TB were reported in 29 European Union and European Economic Area (EU/EEA) countries, resulting in a notification rate of 9.6 per 100,000 population in the EU/EEA. 

Global Tuberculosis Vaccine Market Growth By Region 2022-2028  

Asia-Pacific Emerge as the Fastest-Growing region in Tuberculosis Vaccine Market

Geographically, the Asia-Pacific region is considered to grow at the fastest rate in the tuberculosis vaccine market during the forecast period. The regional growth is attributed to the factors such as the rising number of TB cases growing BCG immunization coverage and rapid technological investments in vaccine development. As per the Indo-Pacific Center for Health Security, nearly two-thirds of the 10 million new cases per year occur in Australia’s neighbors in the South-East Asia and Western Pacific regions. Apart from these, the growing geriatric population in the region’s major economies such as China and India have surged the demand for TB vaccines which include BCG and other booster vaccines. In addition to these factors, the regional market growth is also driven by the development of healthcare infrastructure due to healthcare investment and favorable government policies and initiatives toward TB awareness in underdeveloped countries. 

Market Players Outlook

The major market players in the global tuberculosis vaccine market include Pfizer Inc., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Ltd., Taj Pharmaceuticals Ltd., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2021, TB Alliance and GSK extended their longstanding collaboration to discover new compounds for improving the treatment of tuberculosis (TB). The collaboration between both companies was fundamental to confronting global health challenges. 

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global tuberculosis vaccine market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.